Juričić Gordana, Perović Antonija, Matica Jasminka, Perković-Radojković Kornelija, Horvat Vesna, Mandić Dario, Devčić-Ljubić Tamara, Doljanin Zdravka, Užović Irena, Jedrejčić Katarina, Podolar Sonja, Peran Nena, Severinac Željka, Kelava Ines, Maldini Ivanka, Oršulić Marijan, Kuleš Krešimir
Department of Laboratory Diagnostics, Pula General Hospital, Pula, Croatia.
Medical Biochemistry Laboratory, Glavić Health Care Institution, Dubrovnik, Croatia.
Clin Chem Lab Med. 2025 Sep 8;64(1):215-224. doi: 10.1515/cclm-2025-0536. Print 2026 Jan 27.
In 2023, Croatia implemented a screening program for familial hypercholesterolemia (FH) targeting children entering the first grade of primary school. The program is based on total cholesterol (TC) concentration measurements. This pilot study aimed to assess and compare TC results obtained using different analytical platforms during the program's initial phase (2023-2024).
Retrospective data from laboratories across Croatia were analyzed. Results covered the following analyzers: Beckman Coulter AU (BC), Abbott Alinity/Architect c (AA), Roche Cobas c (RC) and Siemens Atellica CH (SA). Statistical analyses included Kruskal-Wallis and chi-square tests using the program's cut-off values. Bland-Altman and Passing-Bablok analyses were used to assess differences in a direct comparison study of 40 samples. To reduce variability, TC values were also expressed as multiples of the median (MoM), calculated separately for each platform.
The study included 17,694 children. Median TC values (IQR) differed significantly across platforms: BC (4.3 [3.8-4.7] mmol/L), AA (4.1 [3.7-4.5]), RC (4.1 [3.7-4.5]), and SA (4.0 [3.6-4.4]); p<0.001. BC and SA results differed significantly from all other platforms, while no significant difference was found between RC and AA. The distribution of TC results also varied significantly (p<0.001). In the comparison study, all platforms showed statistically significant differences (p<0.001). In contrast, MoM values showed no statistically significant differences between analyzers (p=0.106) or in distribution when applying various MoM-based cut-offs.
Although variations in TC measurements across platforms are small, they are statistically significant and affect FH classification. MoM normalization may support harmonization in future screening protocols.
2023年,克罗地亚实施了一项针对小学一年级入学儿童的家族性高胆固醇血症(FH)筛查计划。该计划基于总胆固醇(TC)浓度测量。这项初步研究旨在评估和比较在该计划初始阶段(2023 - 2024年)使用不同分析平台获得的TC结果。
分析了来自克罗地亚各地实验室的回顾性数据。结果涵盖以下分析仪:贝克曼库尔特AU(BC)、雅培Alinity/Architect c(AA)、罗氏Cobas c(RC)和西门子Atellica CH(SA)。统计分析包括使用该计划的临界值进行的Kruskal - Wallis检验和卡方检验。在对40个样本的直接比较研究中,使用Bland - Altman分析和Passing - Bablok分析来评估差异。为了减少变异性,TC值也表示为中位数倍数(MoM),每个平台分别计算。
该研究纳入了17694名儿童。各平台的TC中位数(IQR)差异显著:BC(4.3 [3.8 - 4.7] mmol/L)、AA(4.1 [3.7 - 4.5])、RC(4.1 [3.7 - 4.5])和SA(4.0 [3.6 - 4.4]);p < 0.001。BC和SA的结果与所有其他平台有显著差异,而RC和AA之间未发现显著差异。TC结果的分布也有显著差异(p < 0.001)。在比较研究中,所有平台均显示出统计学显著差异(p < 0.001)。相比之下,当应用各种基于MoM的临界值时,分析仪之间的MoM值在统计学上无显著差异(p = 0.106),分布上也无显著差异。
尽管各平台间TC测量的差异较小,但在统计学上具有显著性,且会影响FH分类。MoM标准化可能有助于未来筛查方案的统一。